¶ AR Protein — Androgen Receptor
| AR Protein |
|---|
| Protein Name | Androgen Receptor |
| Gene | [AR](/genes/ar) |
| UniProt ID | [P10275](https://www.uniprot.org/uniprot/P10275) |
| PDB ID | 1xwx, 2am9, 2p1n |
| Molecular Weight | ~110 kDa |
| Subcellular Localization | Cytoplasm (unbound) → Nucleus (bound) |
| Protein Family | Nuclear receptor family, NR3 subfamily |
| Expression | Broad: brain, muscle, prostate, liver |
The androgen receptor (AR) is a ligand-activated transcription factor that mediates the effects of androgenic hormones, primarily testosterone and dihydrotestosterone (DHT). Beyond its well-established role in male sexual development and prostate biology, the AR is increasingly recognized for its important functions in the central nervous system, including neuroprotection, cognitive function, and motor control. Mutations in the AR gene cause spinal and bulbar muscular atrophy (SBMA), a progressive neurodegenerative disorder.[1]
The AR protein contains several distinct functional domains:
¶ N-Terminal Domain (NTD; residues 1-537)
The intrinsically disordered N-terminal domain contains:
- Activation Function 1 (AF-1): Transactivation region mediating transcriptional activation
- Polyglutamine (CAG) tract: Normal length 10-36 repeats; expansion causes SBMA
- Multiple phosphorylation sites regulating activity
¶ DNA-Binding Domain (DBD; residues 538-645)
- Two C4-type zinc finger motifs
- Recognition helix contacts androgen response elements (AREs) in DNA
- Dimerization interface
- Nuclear localization signal (NLS)
- Linking region between DBD and LBD
¶ Ligand-Binding Domain (LBD; residues 671-919)
- steroid-binding pocket with high affinity for DHT (Kd ~0.1 nM)
- Contains Activation Function 2 (AF-2)
- Heat shock protein (HSP90) binding site in unliganded state
¶ Androgen Signaling
Upon binding of DHT or testosterone, the AR undergoes a conformational change, dissociates from HSP90, dimerizes, and translocates to the nucleus where it binds to androgen response elements (AREs) in target gene promoters to regulate transcription.[2]
Key target genes include:
- PSA (KLK3): Prostate-specific antigen
- TMPRSS2: Transmembrane protease
- FKBP5: Immunophilin chaperone
- ** neuronal genes**: Including those involved in synaptic plasticity
In the central nervous system, AR signaling exerts neuroprotective effects through:
- Anti-apoptotic signaling: Upregulation of Bcl-2 family proteins
- Antioxidant defense: Enhancement of glutathione peroxidase activity
- Synaptic plasticity: Regulation of NMDA receptor subunit composition
- Myelin maintenance: Support of oligodendrocyte function
AR in the hippocampus and prefrontal cortex regulates:
- Spatial memory consolidation
- Executive function
- Mood and behavior (through limbic system modulation)
¶ Spinal and Bulbar Muscular Atrophy (SBMA)
SBMA, also known as Kennedy's disease, is an X-linked recessive neuromuscular disorder caused by CAG repeat expansion in the AR gene (40-62 repeats). The disease manifests in adulthood with:
- Progressive proximal muscle weakness: Starting in shoulder and pelvic girdle
- Bulbar symptoms: Dysphagia, dysarthria, tongue atrophy
- Affective symptoms: Depression, anxiety
- Metabolic features: Insulin resistance, mild glucose intolerance
The polyglutamine expansion confers toxic gain-of-function:
- Transcriptional dysregulation: Altered binding to AREs
- Proteostasis disruption: Aggregation of mutant AR
- Mitochondrial dysfunction: Impaired energy metabolism
- Excitotoxicity: Enhanced glutamate-induced toxicity
- Impaired autophagy: Reduced clearance of damaged proteins
The mutant AR forms nuclear aggregates that sequester transcription factors and chaperones, disrupting normal gene expression programs essential for motor neuron survival.[3]
Androgen deficiency may contribute to AD pathogenesis:
- Low testosterone levels associated with increased AD risk in men[4]
- AR signaling dysfunction in AD brains
- Testosterone supplementation studies show mixed results on cognitive outcomes
AR may modify PD risk and progression:
- Androgen deprivation therapy associated with increased PD risk
- AR interactions with alpha-synuclein aggregation
- Gender differences in PD prevalence (higher in men)
AR expression in brain metastases from prostate cancer can influence:
- Metastatic colonization
- Treatment resistance to androgen deprivation therapy
- HSP90 inhibitors: Reduce AR aggregation
- Histone deacetylase (HDAC) inhibitors: Modulate transcriptional dysregulation
- Gene silencing: ASO and siRNA approaches targeting mutant AR
- Androgen modulation: Leuprolide to reduce ligand availability
¶ Androgen Therapy in Neurodegeneration
- Testosterone replacement trials in age-related cognitive decline
- Selective androgen receptor modulators (SARMs) for neuroprotection
- DHEA supplementation
- La Spada et al., Nature (1991): Discovery of AR CAG expansion causing SBMA
- Kumar et al., J Mol Endocrinol (2014): Androgen receptor structure and function
- Pennuto et al., Nat Rev Neurol (2015): Pathogenesis and therapy in SBMA
- Pike et al., J Neurosci (2009): Testosterone and brain function in AD
- Finch et al., Neurobiol Aging (2014): Androgens and alpha-synuclein in PD models
[1] Spinal and bulbar muscular atrophy: Pathogenesis and treatment (2015)
[2] Androgen receptor mechanisms in peripheral and central nervous system (2014)
[3] Molecular mechanisms of polyglutamine toxicity in SBMA (2009)
[4] Testosterone and risk of Alzheimer's disease (2009)
[5] HDAC inhibition as therapeutic strategy in SBMA (2018)